cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.5517/ccdc.csd.cc29h7jl
title: CCDC 2129809: Experimental Crystal Structure Determination

description: Related Article: Zhi Wang, Rakesh Kumar Gupta, Fahri Alkan, Bao-Liang Han, Lei Feng, Xian-Qiang Huang, Zhi-Yong Gao, Chen-Ho Tung, Di Sun|2023|J.Am.Chem.Soc.|145|19523|doi:10.1021/jacs.3c01119
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2flkj4
title: CCDC 2252166: Experimental Crystal Structure Determination

description: Related Article: Zhao-Feng Wu, Chuanzhe Wang, Xingwu Liu, Kui Tan, Zhihua Fu, Simon J. Teat, Zi-Wei Li, Xiuze Hei, Xiao-Ying Huang, Gang Xu, Jing Li|2023|J.Am.Chem.Soc.|145|19293|doi:10.1021/jacs.3c05095
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2flkk5
title: CCDC 2252167: Experimental Crystal Structure Determination

description: Related Article: Zhao-Feng Wu, Chuanzhe Wang, Xingwu Liu, Kui Tan, Zhihua Fu, Simon J. Teat, Zi-Wei Li, Xiuze Hei, Xiao-Ying Huang, Gang Xu, Jing Li|2023|J.Am.Chem.Soc.|145|19293|doi:10.1021/jacs.3c05095
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2flkl6
title: CCDC 2252168: Experimental Crystal Structure Determination

description: Related Article: Zhao-Feng Wu, Chuanzhe Wang, Xingwu Liu, Kui Tan, Zhihua Fu, Simon J. Teat, Zi-Wei Li, Xiuze Hei, Xiao-Ying Huang, Gang Xu, Jing Li|2023|J.Am.Chem.Soc.|145|19293|doi:10.1021/jacs.3c05095
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2flkm7
title: CCDC 2252169: Experimental Crystal Structure Determination

description: Related Article: Zhao-Feng Wu, Chuanzhe Wang, Xingwu Liu, Kui Tan, Zhihua Fu, Simon J. Teat, Zi-Wei Li, Xiuze Hei, Xiao-Ying Huang, Gang Xu, Jing Li|2023|J.Am.Chem.Soc.|145|19293|doi:10.1021/jacs.3c05095
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2fr47l
title: CCDC 2256559: Experimental Crystal Structure Determination

description: Related Article: Zhi Wang, Rakesh Kumar Gupta, Fahri Alkan, Bao-Liang Han, Lei Feng, Xian-Qiang Huang, Zhi-Yong Gao, Chen-Ho Tung, Di Sun|2023|J.Am.Chem.Soc.|145|19523|doi:10.1021/jacs.3c01119
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2g8hcm
title: CCDC 2272280: Experimental Crystal Structure Determination

description: Related Article: Seungjin Lee, In Guk Park, Jin Won Choi, Jin Young Son, Jin Woo Lee, Jae-Seoun Hur, Youngmee Kim, Sang-Jip Nam, Hahk-Soo Kang, Stephen T. Deyrup, Minsoo Noh, Sang Hee Shim|2023|Org.Lett.|25|6725|doi:10.1021/acs.orglett.3c02583
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.6084/m9.figshare.24146715
title: Supplementary Material for: IMMUNOHISTOCHEMISTRY, MOLECULAR BIOLOGY AND CLINICAL SCORING FOR THE DETECTION OF MUIR-TORRE SYNDROME IN CUTANEOUS SEBACEOUS TUMORS: WHICH STRATEGY?

description: Background Sebaceous neoplasms (SNs) always raise the possibility of an association with Muir-Torre syndrome (MTS) and permit to screen internal malignancies, colorectal and endometrial carcinomas, before they become symptomatic. Immunohistochemistry (IHC), molecular biology and clinical examination are different approaches for detection of MTS. We conducted a retrospective analysis of non-selected SNs in order to determine the optimal tools to implement for MTS screening. Methods Deficient MMR phenotype (dMMR) was determined by either IHC using antibodies directed to four mismatch repair (MMR) antigens on tissue-microarray or molecular biology using pentaplex PCR. The Mayo-Clinic-Risk score of MTS was calculated from medical records. Sensibility and specificity of each test for the detection of MTS was determined. Results We included 107 patients, 8 with multiple SNs, for a total of 123 SNs (43 sebaceous adenomas, 19 sebaceomas and 61 sebaceous carcinomas (SC)). Loss of at least one MMR protein was observed in 70.7% of tumors while 48% had a microsatellite instable phenotype. Concordance between both techniques was 92.9%, with a 0.85 Cohen’s kappa coefficient. Nineteen patients (20.2%) had a ≥2 points Mayo-Clinic-Risk-Score, one having a pMMR SC. Among the 13 patients with confirmed MTS, 2 had a low Mayo-Clinic-risk score (1 point). IHC had the highest sensitivity for MTS screening (100%) with a specificity of 34.1% while a &gt;2 points Mayo-Clinic-Risk-Score had a lower sensitivity (92%) but a higher specificity (89%). Conclusion To detect MTS in SNs patients, first line Mayo-Clinic-risk-score followed by IHC appears the most accurate strategy with lower cost for society. This strategy should be adapted to the medico-economic resources of each country.
DOI: 10.6084/m9.figshare.24146715.v1
title: Supplementary Material for: IMMUNOHISTOCHEMISTRY, MOLECULAR BIOLOGY AND CLINICAL SCORING FOR THE DETECTION OF MUIR-TORRE SYNDROME IN CUTANEOUS SEBACEOUS TUMORS: WHICH STRATEGY?

description: Background Sebaceous neoplasms (SNs) always raise the possibility of an association with Muir-Torre syndrome (MTS) and permit to screen internal malignancies, colorectal and endometrial carcinomas, before they become symptomatic. Immunohistochemistry (IHC), molecular biology and clinical examination are different approaches for detection of MTS. We conducted a retrospective analysis of non-selected SNs in order to determine the optimal tools to implement for MTS screening. Methods Deficient MMR phenotype (dMMR) was determined by either IHC using antibodies directed to four mismatch repair (MMR) antigens on tissue-microarray or molecular biology using pentaplex PCR. The Mayo-Clinic-Risk score of MTS was calculated from medical records. Sensibility and specificity of each test for the detection of MTS was determined. Results We included 107 patients, 8 with multiple SNs, for a total of 123 SNs (43 sebaceous adenomas, 19 sebaceomas and 61 sebaceous carcinomas (SC)). Loss of at least one MMR protein was observed in 70.7% of tumors while 48% had a microsatellite instable phenotype. Concordance between both techniques was 92.9%, with a 0.85 Cohen’s kappa coefficient. Nineteen patients (20.2%) had a ≥2 points Mayo-Clinic-Risk-Score, one having a pMMR SC. Among the 13 patients with confirmed MTS, 2 had a low Mayo-Clinic-risk score (1 point). IHC had the highest sensitivity for MTS screening (100%) with a specificity of 34.1% while a &gt;2 points Mayo-Clinic-Risk-Score had a lower sensitivity (92%) but a higher specificity (89%). Conclusion To detect MTS in SNs patients, first line Mayo-Clinic-risk-score followed by IHC appears the most accurate strategy with lower cost for society. This strategy should be adapted to the medico-economic resources of each country.
DOI: 10.6084/m9.figshare.24271447.v1
title: Supplementary Material for: Three pediatric patients with congenital nephrogenic diabetes insipidus due to AVPR2 nonsense mutations and different clinical manifestations

description: Congenital nephrogenic diabetes insipidus (CNDI), a rare hereditary disorder, is characterized by the inability of the kidneys to concentrate urine in response to the antidiuretic hormone arginine vasopressin (AVP); as a result, large volumes of unconcentrated urine are excreted. In addition to the clinical manifestations of CNDI, such as dehydration and electrolyte disturbances (hypernatremia and hyperchloremia), developmental delay can result without prompt treatment. In approximately 90% of cases, CNDI is an X-linked disease caused by mutations in the arginine vasopressin receptor 2 (AVPR2) gene. In approximately 9% of cases, CNDI is an autosomal recessive disease caused by mutations in the water channel protein aquaporin 2 (AQP2), and 1% of cases are autosomal dominant. We report a case of CNDI caused by a novel AVPR2 nonsense mutation, c.520C&gt;T (p.Q174X), and cases of siblings in another family who had a different AVPR2 nonsense mutation, c.852G&gt;A (p.W284X). Both cases responded well to treatment with hydrochlorothiazide and spironolactone. If CNDI is suspected especially in carriers and neonates, aggressive genetic testing, and early treatment may alleviate growth disorders and prevent irreversible central nervous system disorders and developmental delay.
DOI: 10.5525/gla.researchdata.1424
title: Prevalence of enterotoxigenic Staphylococcus aureus in raw ruminants’ milk: A systematic review

description: Nature of the data set: Supplementary Excel sheet and an End Note Library. Purpose of the data set: For publication
DOI: 10.34683/sr256
title: StoneRounds Case: SR256
title: AD Cone and Cone Rod Dystrophy

description: StoneRounds Case SR256 was diagnosed with AD Cone and Cone Rod Dystrophy likely caused by mutations in the gene: PROM1.
DOI: 10.6084/m9.figshare.24151692.v1
title: Supplementary Material for: Transcription factor Sox9 exacerbates kidney injury through inhibition of microRNA-96-5p and activation of the Trib3/IL-6 axis

description: Introduction: Our study investigated the possible mechanisms of the role of the transcription factor Sox9 in the development and progression of kidney injury through regulation of the miR-96-5p/Trib3/IL-6 axis. Methods: Bioinformatics analysis was performed to identify differentially expressed genes in kidney injury and normal tissues. An in vivo animal model of kidney injury and an in vitro cellular model of kidney injury were constructed using LPS induction in 8-week-old female C57BL/6 mice and human normal renal tubular epithelial cells HK-2 for studying the possible roles of Sox9, miR-96-5p, Trib3, and IL-6 in kidney injury. Results: Sox9 was highly expressed in both mouse and cellular models of kidney injury. Sox9 was significantly enriched in the promoter region of miR-96-5p and repressed miR-96-5p expression. Trib3 was highly expressed in both mouse and cellular models of kidney injury and promoted inflammatory responses and kidney injury. In addition, Trib3 promoted IL-6 expression, which was highly expressed in kidney injury and promoted the inflammatory response and extent of injury in kidney tissue. In vivo and in vitro experiments confirmed that the knockdown of Sox9 improved the inflammatory response and fibrosis of mouse kidney tissues and HK-2 cells, while the ameliorative effect of silencing Sox9 was inhibited by overexpression of IL-6. Conclusion: Collectively, Sox9 up-regulates miR-96-5p-mediated Trib3 and activates the IL-6 signaling pathway to exacerbate the inflammatory response, ultimately promoting the development and progression of kidney injury.
DOI: 10.6084/m9.figshare.24298330
title: Supplementary Material for: Sealed Unilateral Full-Thickness Macular Hole with Amniotic Membrane Graft in a Patient with Alport Syndrome: A Case Report

description: We present a case of unilateral full-thickness macular hole (MH) successfully repaired with an amniotic membrane graft in a patient with Alport syndrome. A 58-year-old Asian female with past medical history of Alport syndrome diagnosed at early stage, presented with a 5-week history of vision loss in her right eye. Examination of her eyes showed normal retinal vessels and a MH measuring 1300um in basal diameter, 806um in minimum linear diameter, and 490um in height in the right eye and macular thinning with laser scars inferiorly in the left eye. The patient underwent 23 g pars plana vitrectomy with intraocular lens explantation. After multiple unsuccessful attempts in inducing a posterior vitreous detachment around the optic nerve and in the posterior pole, a 1 mm amniotic membrane (AM) graft placed on the MH and the edges tucked under the edges of the hole using a bimanual technique. Five months after surgery, the MH remained sealed with improved final vision. MHs are rare manifestations of Alport syndrome and surgical treatment of Alport syndrome associated MHs is challenging. However, further studies to explore new techniques using AM is needed.
DOI: 10.6084/m9.figshare.24298330.v1
title: Supplementary Material for: Sealed Unilateral Full-Thickness Macular Hole with Amniotic Membrane Graft in a Patient with Alport Syndrome: A Case Report

description: We present a case of unilateral full-thickness macular hole (MH) successfully repaired with an amniotic membrane graft in a patient with Alport syndrome. A 58-year-old Asian female with past medical history of Alport syndrome diagnosed at early stage, presented with a 5-week history of vision loss in her right eye. Examination of her eyes showed normal retinal vessels and a MH measuring 1300um in basal diameter, 806um in minimum linear diameter, and 490um in height in the right eye and macular thinning with laser scars inferiorly in the left eye. The patient underwent 23 g pars plana vitrectomy with intraocular lens explantation. After multiple unsuccessful attempts in inducing a posterior vitreous detachment around the optic nerve and in the posterior pole, a 1 mm amniotic membrane (AM) graft placed on the MH and the edges tucked under the edges of the hole using a bimanual technique. Five months after surgery, the MH remained sealed with improved final vision. MHs are rare manifestations of Alport syndrome and surgical treatment of Alport syndrome associated MHs is challenging. However, further studies to explore new techniques using AM is needed.
DOI: 10.6084/m9.figshare.24145191
title: Supplementary Material for: The safety and efficacy of emergency stenting during bridging therapy: A Single-Center Retrospective Study

description: Introduction: To investigated the safety and efficacy of emergency stenting for patients with ischemic stroke treated with bridging therapy. Methods: Patients with onset of stroke who underwent bridging therapy were included in the two groups with emergency stenting (ESG) and without stenting (NSG). To avoid the bias due to confounding variables, subjects were further assigned in two groups using 1:1 propensity score matching (PSM). The safety outcomes include the incidence of intracranial hemorrhage (ICH), parenchymal hemorrhage type 2 (PH2), symptomatic intracranial hemorrhage (sICH), fatal hemorrhage, and mortality. The efficacy outcomes include successful recanalization, three-month favorable outcome (modified Rankin Scale [mRS]: 0–2). Results: 175 patients treated with bridging therapy were included in this study, with 52 patients in the ES group and 123 patients in the groups without ES, and with 30 patients in each group after PSM. No significant differences in the incidences of ICH, PH2, sICH, fatal hemorrhage, and mortality were found between the two groups with ES and without ES before and after PSM (P&gt;0.05 for all groups). The analysis without PSM showed that the group with ES had a higher rate of successful recanalization (98.1% vs. 81.6%，P=0.041) than the group without ES, but no significant difference was seen (96.6% vs. 93.3%，P=0.554) between the two groups after PSM. There was no difference in favorable outcome between the two groups before and after matching as well (P&gt;0.05). Conclusions: It is safe and effective for patients with onset of ischemic stroke to receive emergency stenting during bridging therapy, without increasing the risk of hemorrhagic transformation and mortality.
DOI: 10.6084/m9.figshare.24145191.v1
title: Supplementary Material for: The safety and efficacy of emergency stenting during bridging therapy: A Single-Center Retrospective Study

description: Introduction: To investigated the safety and efficacy of emergency stenting for patients with ischemic stroke treated with bridging therapy. Methods: Patients with onset of stroke who underwent bridging therapy were included in the two groups with emergency stenting (ESG) and without stenting (NSG). To avoid the bias due to confounding variables, subjects were further assigned in two groups using 1:1 propensity score matching (PSM). The safety outcomes include the incidence of intracranial hemorrhage (ICH), parenchymal hemorrhage type 2 (PH2), symptomatic intracranial hemorrhage (sICH), fatal hemorrhage, and mortality. The efficacy outcomes include successful recanalization, three-month favorable outcome (modified Rankin Scale [mRS]: 0–2). Results: 175 patients treated with bridging therapy were included in this study, with 52 patients in the ES group and 123 patients in the groups without ES, and with 30 patients in each group after PSM. No significant differences in the incidences of ICH, PH2, sICH, fatal hemorrhage, and mortality were found between the two groups with ES and without ES before and after PSM (P&gt;0.05 for all groups). The analysis without PSM showed that the group with ES had a higher rate of successful recanalization (98.1% vs. 81.6%，P=0.041) than the group without ES, but no significant difference was seen (96.6% vs. 93.3%，P=0.554) between the two groups after PSM. There was no difference in favorable outcome between the two groups before and after matching as well (P&gt;0.05). Conclusions: It is safe and effective for patients with onset of ischemic stroke to receive emergency stenting during bridging therapy, without increasing the risk of hemorrhagic transformation and mortality.
DOI: 10.6084/m9.figshare.24138987.v1
title: Supplementary Material for: Incidence and predictors of esophagogastric varices bleeding in patients with hepatocellular carcinoma in lenvatinib

description: Introduction: Lenvatinib is indicated for the forefront treatment of advanced hepatocellular carcinoma (aHCC), but its use maybe limited by the risk of esophagogastric varices (EGV) bleeding. This study assessed the prevalence, predictors, and complications of EGV in aHCC patients treated with lenvatinib. Methods: In this multicenter international retrospective study, cirrhotic patients treated with lenvatinib for aHCC, were enrolled if upper-gastrointestinal endoscopy (UGE) available within 6 months before treatment. Primary endpoint was the incidence of EGV bleeding during lenvatinib therapy; secondary endpoints were predictors for EGV bleeding, prevalence and risk factors for the presence of EGV and high risk EGV at baseline, impact of EGV bleeding on patients’ survival. Results: 535 patients were enrolled in the study [median age 72 years, 78% male, 63% viral aetiology, 89% Child-Pugh A, 16% neoplastic portal vein thrombosis (nPVT), 56% BCLC-C]: 234 had EGV (44%): 70 (30%) at high-risk and 59 on primary prophylaxis. During lenvatinib treatment, 17 patients bled from EGV (3 grade 5), the 12-month cumulative incidence being 3%. The only baseline independent predictor of EGV bleeding was the presence of baseline high risk EGV (HR 6.94, 95% CI 2.23-21.57, p=0.001). In these patients the 12-month risk was 17%. High risk varices were independently associated with Child-Pugh B score (OR 2.12; 95%CI 1.08-4.17, p=0.03), nPVT (OR 2.54; 95%CI 1.40-4.61, p=0.002) and platelets &lt;150.000/uL (OR 2.47; 95%CI 1.35-4.50, p=0.003. Conclusion: In HCC patients treated with lenvatinib, the risk of EGV bleeding was mostly low but significant only in patients with high-risk EGV at baseline.
DOI: 10.21227/njx8-xn39
title: Ultrasonic Doppler Flowmeter

description: We collected relevant data of ultrasonic Doppler flowmeter in the laboratory to study the error of ultrasonic Doppler flowmeter. It contains four sets of data at different turbidities and four sets of data at different liquid levels. Each set of data under different turbidities contains 440 pieces of data, and each set of experiments under different liquid levels contains 220 pieces of data. The entire data set has a total of 2720 pieces of data. The training set test split is 8:2, which we have already split in the uploaded data set. In addition, ultrasonic Doppler flowmeter data includes instantaneous flow, liquid level, turbidity and flow rate. Electromagnetic flow meters only contain instantaneous flow.
DOI: 10.6084/m9.figshare.24347143
title: Supplementary Data of <b>MODELING MAXIMAL OXYGEN UPTAKE AND MAXIMAL POWER OUTPUT BY BODY-MASS IN COMPETITIVE ENDURANCE CYCLIST</b><b>S</b>

description: Supplementary data of the manuscript <b>MODELING MAXIMAL OXYGEN UPTAKE AND MAXIMAL POWER OUTPUT BY BODY-MASS IN COMPETITIVE ENDURANCE CYCLISTS</b>
DOI: 10.6084/m9.figshare.24316306.v1
title: Supplementary Material for: Gastric Conduit Cancer Following Ivor-Lewis Esophagectomy for Esophageal Adenocarcinoma: A Case Report and Literature Review

description: The incidence of gastric cancer associated with esophageal cancer is notably high. In recent years, there has been an increase in patients with gastric conduit cancers due to early detection and radical treatment of esophageal cancer, leading to prolonged survival of the patients. Metachronous gastric cancer following esophagectomy sometimes can pose a clinical challenge for surgeons: while gastric tube reconstruction is a well-established procedure accompanying esophagectomy, treating gastric cancer within the gastric tube can be difficult in contrast. Surgical treatment of gastric tube cancers is often complex and life-threatening. Early detection of gastric tube cancer is crucial for improving prognosis, as it allows for less invasive surgical interventions. However, no specific guidelines for detecting gastric tube cancer have been established. In this report, we present a case of gastric tube cancer in a patient that had Ivor-Lewis surgery 20 years ago for preinvasive adenocarcinoma of the thoracic esophagus against the background of Barrett’s esophagus. Recommendations for earlier and more accurate diagnosis and treatment of this pathology are discussed.